Nektar And Collaborators Present Late-Breaking Results From Phase 2 Study Of NKTR-255 For The Treatment Of Radiation Induced Lymphopenia In Locally Advanced Non-Small Cell Lung Cancer Patients At SITC Annual Meeting; Demonstrated Statistically...
Nektar And Collaborators Present Late-Breaking Results From Phase 2 Study Of NKTR-255 For The Treatment Of Radiation Induced Lymphopenia In Locally Advanced Non-Small Cell Lung Cancer Patients At SITC Annual Meeting; Demonstrated Statistically...
Nektar And Collaborators Present Late-Breaking Results From Phase 2 Study Of NKTR-255 For The Treatment Of Radiation Induced Lymphopenia In Locally Advanced Non-Small Cell Lung Cancer Patients At SITC Annual Meeting; Demonstrated Statistically Significant Lymphocyte Recovery Compared To Historical Controls At Week 8
内克塔及合作伙伴在海丰国际年会上发布了阶段2研究NKTR-255治疗局部晚期非小细胞肺癌患者放疗引起的淋巴减少的最新结果；在第8周与历史对照组相比，显示出具有统计学意义的淋巴细胞恢复。
– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 –
- 在完成同时化疗放疗后给予NKTR-255，并与durvalumab联合使用，在第8周显示出与历史对照组相比具有显着统计学意义的淋巴细胞恢复。 -
– Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell activation –
- 药效动力学数据显示NKTR-255增加了Nk细胞增殖和Nk细胞激活标志物 -
SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) and collaborators at The University of Texas MD Anderson Cancer Center today presented late-breaking results from a Phase 2 study evaluating NKTR-255 for the treatment of radiation induced lymphopenia after concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
2024年11月7日，旧金山/美通社/ -- 内克塔治疗（纳斯达克股票代码：NKTR）与德克萨斯大学MD安德森癌症中心的合作伙伴今日在海丰国际第39届年会上发布了一项阶段2研究的最新结果，评估了NKTR-255用于治疗局部晚期非小细胞肺癌患者在完成同时化疗放疗后放疗引起的淋巴减少。
